Salivary Glycopatterns as Potential Biomarkers for Screening of Early-Stage Breast Cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29402727.
- Also identified by DOI 10.1016/j.ebiom.2018.01.026 and PMC identifier 5898026.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We systematically investigated and assessed the alterations of salivary glycopatterns and possibility as biomarkers for diagnosis of early-stage breast cancer. Alterations of salivary glycopatterns were probed using lectin microarrays and blotting analysis from 337 patients with breast benign cyst or tumor (BB) or breast cancer (I/II stage) and 110 healthy humans. Their diagnostic models were constructed by a logistic stepwise regression in the retrospective cohort. Then, the performance of the diagnostic models were assessed by ROC analysis in the validation cohort. Finally, a double-blind cohort was tested to confirm the application potential of the diagnostic models. The diagnostic models were constructed based on 9 candidate lectins (e.g., PHA-E+L, BS-I, and NPA) that exhibited significant alterations of salivary glycopatterns, which achieved better diagnostic powers with an AUC value >0.750 (p<0.001) for the diagnosis of BB (AUC: 0.752, sensitivity: 0.600, and specificity: 0.835) and I stage breast cancer (AUC: 0.755, sensitivity: 0.733, and specificity: 0.742) in the validation cohort. The diagnostic model of I stage breast cancer exhibited a high accuracy of 0.902 in double-blind cohort. This study could contribute to the screening for patients with early-stage breast cancer based on precise alterations of salivary glycopatterns.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms
- Early Detection of Cancer
- Glycomics
- Saliva